

# Bo Ahrn

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7087299/bo-ahren-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

425  
papers

20,609  
citations

74  
h-index

126  
g-index

442  
ext. papers

22,153  
ext. citations

6.2  
avg, IF

7.25  
L-index

#	Paper	IF	Citations
4 <sup>25</sup>	Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1316-22	59.2	764
4 <sup>24</sup>	The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. <i>Diabetes</i> , <b>2004</b> , 53 Suppl 3, S215-9	0.9	713
4 <sup>23</sup>	Autonomic regulation of islet hormone secretion—implications for health and disease. <i>Diabetologia</i> , <b>2000</b> , 43, 393-410	10.3	687
4 <sup>22</sup>	Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2078-84	5.6	611
4 <sup>21</sup>	Islet amyloid and type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 411-9	59.2	439
4 <sup>20</sup>	Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 2874-80	14.6	429
4 <sup>19</sup>	Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 869-75	14.6	383
4 <sup>18</sup>	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , <b>2009</b> , 8, 369-85	64.1	323
4 <sup>17</sup>	Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. <i>Diabetes Care</i> , <b>2005</b> , 28, 1936-40	14.6	271
4 <sup>16</sup>	Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. <i>Diabetologia</i> , <b>1986</b> , 29, 827-36	10.3	254
4 <sup>15</sup>	Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. <i>Endocrinology</i> , <b>2003</b> , 144, 916-21	4.8	237
4 <sup>14</sup>	Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 157-66	6.7	231
4 <sup>13</sup>	The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. <i>Diabetes</i> , <b>2001</b> , 50, 1030-8	0.9	223
4 <sup>12</sup>	Alpha cell function in health and disease: influence of glucagon-like peptide-1. <i>Diabetologia</i> , <b>2005</b> , 48, 1700-13	10.3	221
4 <sup>11</sup>	Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 112-20	6.7	195
4 <sup>10</sup>	A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. <i>Diabetologia</i> , <b>2007</b> , 50, 1795-1807	10.3	190
4 <sup>09</sup>	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 341-354	18.1	189

408	GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. <i>Hormone and Metabolic Research</i> , <b>2004</b> , 36, 867-76	3.1	187
407	Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. <i>Diabetes</i> , <b>1998</b> , 47, 995-1005	0.9	174
406	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. <i>Diabetes Care</i> , <b>2014</b> , 37, 2317-25	14.6	173
405	Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. <i>European Journal of Endocrinology</i> , <b>2004</b> , 150, 97-104	6.5	173
404	Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. <i>Diabetes Care</i> , <b>2001</b> , 24, 1640-5	14.6	172
403	HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. <i>Diabetes Care</i> , <b>2014</b> , 37, 2141-8	14.6	166
402	Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 1236-43	5.6	164
401	Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 780-9	6.7	163
400	Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. <i>Diabetes Care</i> , <b>2007</b> , 30, 1344-50	14.6	160
399	Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 717-27	6.5	156
398	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 1091-102	5.9	155
397	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. <i>European Journal of Pharmacology</i> , <b>2000</b> , 404, 239-45	5.3	153
396	PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, 1307-15	15.9	149
395	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 762-7	6.7	147
394	Incretin and islet hormonal responses to fat and protein ingestion in healthy men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 295, E779-84	6	133
393	DPP-4 inhibitors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 21, 517-33	6.5	133
392	Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2519-24	5.6	131
391	Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). <i>Diabetes Care</i> , <b>2013</b> , 36, 2543-50	14.6	129

390	G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes <b>2007</b> , 116, 437-48		128
389	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2013</b> , 9, 155-63	4.4	119
388	Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 473-8	5.6	118
387	Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 775-83	6.7	114
386	Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. <i>Cell and Tissue Research</i> , <b>1992</b> , 269, 275-9	4.2	114
385	Dissociated insulintropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. <i>Metabolism: Clinical and Experimental</i> , <b>1997</b> , 46, 97-106	12.7	111
384	Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon. <i>Endocrinology</i> , <b>1987</b> , 121, 323-31	4.8	111
383	Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 872-8	5.6	106
382	Type 2 diabetes, insulin secretion and beta-cell mass. <i>Current Molecular Medicine</i> , <b>2005</b> , 5, 275-86	2.5	105
381	Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. <i>Endocrinology</i> , <b>2006</b> , 147, 3173-80	4.8	104
380	Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. <i>Diabetes Care</i> , <b>1996</b> , 19, 843-8	14.6	101
379	Gut peptides and type 2 diabetes mellitus treatment. <i>Current Diabetes Reports</i> , <b>2003</b> , 3, 365-72	5.6	101
378	The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. <i>Endocrinology</i> , <b>1986</b> , 118, 1551-7	4.8	101
377	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 473-478	5.6	100
376	Neuropeptide Y: intrapancreatic neuronal localization and effects on insulin secretion in the mouse. <i>Cell and Tissue Research</i> , <b>1987</b> , 248, 43-8	4.2	98
375	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1693-701	14.6	98
374	Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1997</b> , 273, R113-20	3.2	96
373	Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. <i>Diabetes</i> , <b>2006</b> , 55, 3463-9	0.9	96

372	Improved beta-cell function after standardized weight reduction in severely obese subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2003</b> , 284, E557-65	6	96
371	Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. <i>Diabetologia</i> , <b>2014</b> , 57, 1807-11	10.3	95
370	Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. <i>Acta Physiologica Scandinavica</i> , <b>1997</b> , 160, 413-22		94
369	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. <i>Diabetes</i> , <b>2016</b> , 65, 3473-3481	0.9	93
368	Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. <i>BioEssays</i> , <b>1998</b> , 20, 642-51	4.1	91
367	Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2001</b> , 281, E693-703	6	90
366	Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1820-6	14.6	83
365	Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. <i>Endocrinology</i> , <b>2005</b> , 146, 2055-9	4.8	83
364	Physiology of incretins in health and disease. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 293-306	3.6	83
363	Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 487-98	6.5	82
362	Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. <i>Diabetologia</i> , <b>1998</b> , 41, 772-7	10.3	81
361	GPR40 is expressed in glucagon producing cells and affects glucagon secretion. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 354, 240-5	3.4	81
360	Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. <i>European Journal of Endocrinology</i> , <b>1998</b> , 139, 461-7	6.5	80
359	Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. <i>Metabolism: Clinical and Experimental</i> , <b>2004</b> , 53, 624-31	12.7	78
358	Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. <i>Diabetes Care</i> , <b>2000</b> , 23, 650-7	14.6	77
357	Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2004</b> , 286, R269-72	3.2	76
356	Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. <i>Diabetologia</i> , <b>2001</b> , 44, 1998-2003	10.3	75
355	Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion. <i>Cell and Tissue Research</i> , <b>1990</b> , 261, 49-58	4.2	75

- 354 Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. *Diabetes*, **2014**, 63, 2196-2020.9 74
- 353 Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3799-806 74
- 352 Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care*, **2010**, 33, 730-2 14.6 74
- 351 Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. *Diabetologia*, **2005**, 48, 748-51 10.3 74
- 350 GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. *Diabetes Care*, **1997**, 20, 1874-9 14.6 73
- 349 The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. *Diabetes*, **2001**, 50, 1959-69 0.9 72
- 348 Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. *Diabetes*, **1997**, 46, 801-7 0.9 71
- 347 Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. *Expert Opinion on Emerging Drugs*, **2008**, 13, 593-607 3.7 71
- 346 High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. *Diabetologia*, **2015**, 58, 912-9 10.3 70
- 345 Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. *Diabetes Care*, **2017**, 40, 1573-1579 14.6 70
- 344 Diurnal variation in circulating leptin is dependent on gender, food intake and circulating insulin in mice. *Acta Physiologica Scandinavica*, **2000**, 169, 325-31 69
- 343 Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1998**, 274, R1482-913.2 69
- 342 Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular distribution and effects on stimulated insulin secretion in the mouse. *Endocrinology*, **1979**, 104, 832-8 4.8 68
- 341 Role of VIP and PACAP in islet function. *Peptides*, **2007**, 28, 1805-13 3.8 67
- 340 Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. *Expert Opinion on Investigational Drugs*, **2006**, 15, 431-42 5.9 67
- 339 Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. *Diabetes Care*, **2003**, 26, 2860-4 14.6 66
- 338 Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2002**, 283, E738-44 66
- 337 Glucagon immunoreactivity in plasma from normal and dystrophic mice. *Diabetologia*, **1982**, 22, 258-63 10.3 65

336	GLP-1 for type 2 diabetes. <i>Experimental Cell Research</i> , <b>2011</b> , 317, 1239-45	4.2	64
335	Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 3093-8	5.6	64
334	Islet adaptation to insulin resistance: mechanisms and implications for intervention. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 2-8	6.7	64
333	Glucagon--Early breakthroughs and recent discoveries. <i>Peptides</i> , <b>2015</b> , 67, 74-81	3.8	63
332	Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. <i>Endocrinology</i> , <b>2004</b> , 145, 3190-6	4.8	63
331	Increased $\beta$ cell volume in mice fed a high-fat diet: a dynamic study over 12 months. <i>Islets</i> , <b>2010</b> , 2, 353-6	2	61
330	Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice. <i>Diabetes</i> , <b>1988</b> , 37, 281-5	0.9	61
329	Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse. <i>Acta Physiologica Scandinavica</i> , <b>1987</b> , 129, 305-9		60
328	Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2887-92	5.6	58
327	Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. <i>Diabetologia</i> , <b>2000</b> , 43, 194-202	10.3	58
326	Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. <i>Diabetologia</i> , <b>2014</b> , 57, 1876-83	10.3	57
325	Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin. <i>Obesity</i> , <b>2008</b> , 16, 1019-24	8	57
324	Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1043-8	5.6	56
323	GLP-1 and GLP-17-36 Amide. <i>Pancreas</i> , <b>1991</b> , 6, 208-215	2.6	56
322	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1043-1048	5.6	56
321	PACAP and PACAP receptors in insulin producing tissues: localization and effects. <i>Regulatory Peptides</i> , <b>1998</b> , 74, 167-75		55
320	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 383-94	4.4	55
319	Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. <i>Diabetologia</i> , <b>1999</b> , 42, 936-43	10.3	55

318	Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. <i>Diabetes</i> , <b>2014</b> , 63, 101-10	0.9	54
317	Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. <i>Diabetologia</i> , <b>2007</b> , 50, 1453-62	10.3	54
316	Assessment of insulin secretion in relation to insulin resistance. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2005</b> , 8, 529-33	3.8	54
315	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. <i>Diabetologia</i> , <b>1996</b> , 39, 1099-107	10.3	54
314	Regulation of circulating leptin in humans. <i>Endocrine</i> , <b>1997</b> , 7, 1-8		53
313	GLP-1 and extra-islet effects. <i>Hormone and Metabolic Research</i> , <b>2004</b> , 36, 842-5	3.1	53
312	Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. <i>Diabetologia</i> , <b>2013</b> , 56, 1752-60	10.3	52
311	Galanin and the endocrine pancreas. <i>FEBS Letters</i> , <b>1988</b> , 229, 233-7	3.8	51
310	Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. <i>Diabetes</i> , <b>2009</b> , 58, 726-31	0.9	50
309	Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 321, 916-21	3.4	50
308	The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. <i>International Journal of Clinical Practice</i> , <b>2008</b> , 62, 8-14	2.9	49
307	Plasma leptin and insulin in C57Bl/6J mice on a high-fat diet: relation to subsequent changes in body weight. <i>Acta Physiologica Scandinavica</i> , <b>1999</b> , 165, 233-40		49
306	The future of incretin-based therapy: novel avenues--novel targets. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13 Suppl 1, 158-66	6.7	48
305	Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. <i>Journal of Internal Medicine</i> , <b>1995</b> , 237, 537-41	10.8	48
304	Cholecystokinin and the regulation of insulin secretion. <i>Scandinavian Journal of Gastroenterology</i> , <b>1992</b> , 27, 161-5	2.4	48
303	Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 15214-22	5.4	46
302	Acylation stimulating protein stimulates insulin secretion. <i>International Journal of Obesity</i> , <b>2003</b> , 27, 1037-43	5.4	46
301	Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. <i>Diabetes and Metabolism</i> , <b>2013</b> , 39, 195-201	5.4	45



300	Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 193-203	6.7	45
299	Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. <i>Diabetologia</i> , <b>2005</b> , 48, 2140-6	10.3	45
298	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ, The</i> , <b>2015</b> , 351, h5364	5.9	44
297	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. <i>Diabetologia</i> , <b>2016</b> , 59, 907-17	10.3	44
296	Age-related reduction in glucose elimination is accompanied by reduced glucose effectiveness and increased hepatic insulin extraction in man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 3350-6	5.6	44
295	Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. <i>Diabetes Research and Clinical Practice</i> , <b>1991</b> , 13, 153-61	7.4	44
294	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2210-2219	6.7	44
293	Body adiposity, insulin, and leptin in subgroups of Peruvian Amerindians. <i>High Altitude Medicine and Biology</i> , <b>2004</b> , 5, 27-31	1.9	43
292	Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 812-8	6.7	42
291	Incretin effect after oral amino acid ingestion in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1172-6	5.6	42
290	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. <i>World Journal of Diabetes</i> , <b>2014</b> , 5, 40-51	4.7	42
289	Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. <i>European Journal of Endocrinology</i> , <b>1997</b> , 137, 127-31	6.5	42
288	Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2000</b> , 279, E956-62	6	42
287	Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets. <i>Cell and Tissue Research</i> , <b>1991</b> , 264, 263-7	4.2	42
286	Galanin-immunoreactive nerves in the mouse and rat pancreas. <i>Cell and Tissue Research</i> , <b>1991</b> , 264, 363-8	4.2	42
285	Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells. <i>Endocrinology</i> , <b>1996</b> , 137, 2791-8	4.8	41
284	Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2068-74	5.6	40
283	Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. <i>Diabetologia</i> , <b>2014</b> , 57, 1304-7	10.3	38

282	Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2006</b> , 290, E347-54	6	38
281	Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. <i>Journal of Nutritional Biochemistry</i> , <b>2004</b> , 15, 579-82	6.3	38
280	Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. <i>Cell and Tissue Research</i> , <b>1992</b> , 269, 315-22	4.2	38
279	Methods and models for metabolic assessment in mice. <i>Journal of Diabetes Research</i> , <b>2013</b> , 2013, 986906	9.9	37
278	Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. <i>Hormone and Metabolic Research</i> , <b>2007</b> , 39, 826-9	3.1	37
277	DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. <i>Regulatory Peptides</i> , <b>2007</b> , 143, 97-103		37
276	Islet dysfunction in obese women with impaired glucose tolerance. <i>Metabolism: Clinical and Experimental</i> , <b>1996</b> , 45, 502-9	12.7	37
275	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 376	5.7	36
274	Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice. <i>Metabolism: Clinical and Experimental</i> , <b>2007</b> , 56, 122-8	12.7	36
273	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. <i>Current Diabetes Reports</i> , <b>2007</b> , 7, 340-7	5.6	36
272	Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. <i>European Journal of Pharmacology</i> , <b>2005</b> , 509, 211-7	5.3	36
271	Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1999</b> , 277, E996-E1004	6	36
270	Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. <i>Diabetologia</i> , <b>1998</b> , 41, 1374-80	10.3	35
269	Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. <i>Diabetes</i> , <b>2002</b> , 51 Suppl 1, S202-11	0.9	35
268	Incretin hormone secretion over the day. <i>Vitamins and Hormones</i> , <b>2010</b> , 84, 203-20	2.5	34
267	Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. <i>European Journal of Pharmacology</i> , <b>2010</b> , 626, 297-305	5.3	34
266	Gastrin releasing peptide (GRP): effects on basal and stimulated insulin and glucagon secretion in the mouse. <i>Peptides</i> , <b>1987</b> , 8, 55-60	3.8	34
265	Effect of dietary fibre on blood glucose, plasma immunoreactive insulin, C-peptide and GIP responses in non insulin dependent (type 2) diabetics and controls. <i>Acta Medica Scandinavica</i> , <b>1984</b> , 215, 205-13		33

264	Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1995</b> , 80, 1778-82	5.6	33
263	Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. <i>Acta Physiologica Scandinavica</i> , <b>1990</b> , 139, 591-6		33
262	Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 921, 259-63	6.5	32
261	Pharmacokinetics of human leptin in mice and rhesus monkeys. <i>International Journal of Obesity</i> , <b>2000</b> , 24, 1579-85	5.5	32
260	Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 251, 888-93	3.4	32
259	Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. <i>Molecular and Cellular Endocrinology</i> , <b>1995</b> , 114, 101-9	4.4	32
258	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2171-2180	14.6	31
257	DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 473, 186-193	4.4	31
256	High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA in Type 2 diabetes. <i>Journal of Nutritional Biochemistry</i> , <b>2017</b> , 49, 1-7	6.3	31
255	Differential development of glucose intolerance and pancreatic islet adaptation in multiple diet induced obesity models. <i>Nutrients</i> , <b>2012</b> , 4, 1367-81	6.7	31
254	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 31-41	3.4	31
253	Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 342, 1174-7	3.4	31
252	Effects of alpha-adrenoceptor blockade by phentolamine on basal and stimulated insulin secretion in the mouse. <i>Acta Physiologica Scandinavica</i> , <b>1985</b> , 125, 211-7		31
251	Age-Related Reduction in Glucose Elimination Is Accompanied by Reduced Glucose Effectiveness and Increased Hepatic Insulin Extraction in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 3350-3356	5.6	31
250	Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1144, 28-35	6.5	30
249	Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. <i>Endocrinology</i> , <b>2003</b> , 144, 5293-9	4.8	30
248	Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretion. <i>Journal of the Autonomic Nervous System</i> , <b>1992</b> , 39, 51-9		30
247	Effects of alpha 1- and alpha 2-adrenoceptor stimulation and blockade on plasma insulin levels in the mouse. <i>Pancreas</i> , <b>1986</b> , 1, 415-20	2.6	30

246	Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. <i>European Journal of Endocrinology</i> , <b>1983</b> , 102, 96-102	6.5	30
245	The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. <i>Journal of Endocrinology</i> , <b>2008</b> , 197, 181-7	4.7	29
244	Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995. <i>British Journal of Surgery</i> , <b>1988</b> , 75, 718	5.3	29
243	DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. <i>Diabetologia</i> , <b>2015</b> , 58, 1091-9	10.3	28
242	Modulation of basal insulin secretion in the obese, hyperglycemic mouse. <i>Metabolism: Clinical and Experimental</i> , <b>1982</b> , 31, 172-9	12.7	28
241	Glucagon secretion in relation to insulin sensitivity in healthy subjects. <i>Diabetologia</i> , <b>2006</b> , 49, 117-22	10.3	27
240	Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2000</b> , 278, E684-E691	6	27
239	Effects of amidated rat islet amyloid polypeptide on glucose-stimulated insulin secretion in vivo and in vitro in rats. <i>European Journal of Pharmacology</i> , <b>1991</b> , 192, 443-5	5.3	27
238	Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 531-7	6.7	26
237	Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2006</b> , 1761, 256-60	5	26
236	Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. <i>Acta Physiologica Scandinavica</i> , <b>2001</b> , 171, 161-7		26
235	Potentiated beta-cell response to non-glucose stimuli in insulin-resistant C57BL/6J mice. <i>European Journal of Pharmacology</i> , <b>1998</b> , 350, 243-50	5.3	26
234	PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 274, E834-42	6	26
233	Effects of autonomic blockade by methylatropine and optical isomers and propranolol on plasma insulin levels in the basal state and after stimulation. <i>Acta Physiologica Scandinavica</i> , <b>1981</b> , 112, 57-63		26
232	Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. <i>European Journal of Pharmacology</i> , <b>2011</b> , 663, 80-6	5.3	25
231	Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1264-70	5.6	25
230	Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. <i>European Journal of Pharmacology</i> , <b>2005</b> , 521, 164-8	5.3	25
229	Islet function phenotype in gastrin-releasing peptide receptor gene-deficient mice. <i>Endocrinology</i> , <b>2002</b> , 143, 3717-26	4.8	25

228	Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1999</b> , 277, E93-102	6	25
227	Inhibition of Dipeptidyl Peptidase-4 (DPP-4) - A Novel Approach to Treat Type 2 Diabetes. <i>Current Enzyme Inhibition</i> , <b>2005</b> , 1, 65-73	0.5	24
226	Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells). <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1999</b> , 277, R959-66	3.2	24
225	Insulinotropic action of truncated glucagon-like peptide-1 in mice. <i>Acta Physiologica Scandinavica</i> , <b>1995</b> , 153, 205-6		24
224	GIP-like immunoreactivity in glucagon cells. Interactions between GIP and glucagon on insulin release. <i>Acta Physiologica Scandinavica</i> , <b>1981</b> , 112, 233-42		24
223	Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 196-201	3.9	23
222	Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. <i>Regulatory Peptides</i> , <b>2012</b> , 178, 29-35		23
221	Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. <i>Endocrine Connections</i> , <b>2013</b> , 2, 69-78	3.5	23
220	Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. <i>Vascular Health and Risk Management</i> , <b>2013</b> , 9, 57-64	4.4	23
219	Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. <i>European Journal of Endocrinology</i> , <b>1996</b> , 134, 362-5	6.5	23
218	Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. <i>Journal of Internal Medicine</i> , <b>2001</b> , 250, 81-7	10.8	23
217	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. <i>European Journal of Endocrinology</i> , <b>1990</b> , 123, 591-597	6.5	23
216	Studies on the mechanism by which galanin inhibits insulin secretion in islets. <i>European Journal of Pharmacology</i> , <b>1991</b> , 205, 21-7	5.3	23
215	Islet nerves in focus--defining their neurobiological and clinical role. <i>Diabetologia</i> , <b>2012</b> , 55, 3152-4	10.3	22
214	Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men. <i>European Journal of Clinical Nutrition</i> , <b>2009</b> , 63, 778-86	5.2	22
213	PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. <i>Regulatory Peptides</i> , <b>2003</b> , 113, 31-9		22
212	Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 453, 398-404	3.4	21
211	Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 861-8	6.7	21

210	Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1997</b> , 273, E701-7	6	21
209	Glucagon-like peptide-1 and islet lipolysis. <i>Hormone and Metabolic Research</i> , <b>2004</b> , 36, 795-803	3.1	21
208	1,5-Anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. <i>European Journal of Pharmacology</i> , <b>2000</b> , 397, 219-25	5.3	21
207	PACAP contributes to insulin secretion after gastric glucose gavage in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2000</b> , 279, R424-32	3.2	21
206	Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1994</b> , 267, R1071-7	3.2	21
205	Effects of galanin on insulin and glucagon secretion in the rat. <i>International Journal of Gastrointestinal Cancer</i> , <b>1989</b> , 4, 335-44		21
204	The mechanism of 2-deoxy-glucose-induced insulin secretion in the mouse. <i>Autonomic and Autacoid Pharmacology</i> , <b>1987</b> , 7, 135-44		21
203	VIP-stimulated thyroid hormone secretion: effects of other neuropeptides and alpha- or beta-adrenoceptor blockade. <i>Acta Physiologica Scandinavica</i> , <b>1982</b> , 114, 471-3		21
202	Clinical measures of islet function: usefulness to characterize defects in diabetes. <i>Current Diabetes Reviews</i> , <b>2008</b> , 4, 129-45	2.7	21
201	Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 442-447	6.7	20
200	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 50-7	2.1	20
199	Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?. <i>Current Diabetes Reports</i> , <b>2011</b> , 11, 83-90	5.6	20
198	Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B. <i>Journal of Endocrinology</i> , <b>2006</b> , 189, 629-41	4.7	20
197	The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. <i>Acta Physiologica Scandinavica</i> , <b>2002</b> , 175, 25-8		20
196	CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion. <i>Diabetologia</i> , <b>2016</b> , 59, 1928-37	10.3	19
195	Incretin and islet hormone responses to meals of increasing size in healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 561-8	5.6	19
194	Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2009</b> , 296, R1316-24	3.2	19
193	Basic toxicology and metabolism studies of 1,5-anhydro-D-fructose using bacteria, cultured mammalian cells, and rodents. <i>Food and Chemical Toxicology</i> , <b>2004</b> , 42, 1677-86	4.7	19

192	Exenatide: a novel treatment of Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 207-222		19
191	Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. <i>Metabolism: Clinical and Experimental</i> , <b>2000</b> , 49, 1518-22	12.7	19
190	Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. <i>Diabetes Research and Clinical Practice</i> , <b>1992</b> , 15, 219-26	7.4	19
189	GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat. <i>Regulatory Peptides</i> , <b>2014</b> , 189, 40-5		18
188	Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships. <i>Acta Medica Scandinavica</i> , <b>1987</b> , 221, 185-90		18
187	Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. <i>Diabetologia</i> , <b>2008</b> , 51, 1018-24	10.3	18
186	Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. <i>American Journal of Clinical Nutrition</i> , <b>2006</b> , 84, 1009-13	7	18
185	Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. <i>Peptides</i> , <b>2017</b> , 88, 74-79	3.8	17
184	Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women: A dissociation contributing to low blood pressure?. <i>Metabolism: Clinical and Experimental</i> , <b>2001</b> , 50, 325-9	12.7	17
183	Muscarinic receptor subtypes in carbachol-stimulated insulin and glucagon secretion in the mouse. <i>Autonomic and Autacoid Pharmacology</i> , <b>1993</b> , 13, 439-446		17
182	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 126, 230-239	7.4	16
181	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 131, 49-60	7.4	16
180	Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjects. <i>Diabetes Care</i> , <b>2007</b> , 30, 644-8	14.6	16
179	Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion. <i>European Journal of Pharmacology</i> , <b>1993</b> , 236, 69-74	5.3	16
178	Contribution of galanin to stress-induced impairment of insulin secretion in swimming mice. <i>Acta Physiologica Scandinavica</i> , <b>1991</b> , 143, 145-52		16
177	Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. <i>International Journal of Gastrointestinal Cancer</i> , <b>1990</b> , 6, 1-15		16
176	Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. <i>Diabetes</i> , <b>1997</b> , 46, 801-807	0.9	16
175	DPP-4 inhibition and islet function. <i>Journal of Diabetes Investigation</i> , <b>2012</b> , 3, 3-10	3.9	15

174	Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 863-5	6.7	15
173	What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. <i>Diabetologia</i> , <b>2005</b> , 48, 605-7	10.3	15
172	Augmented insulinotropic action of arachidonic acid through the lipoxygenase pathway in the obese Zucker rat. <i>Obesity</i> , <b>2000</b> , 8, 475-80		15
171	Leptin increases circulating glucose, insulin and glucagon via sympathetic neural activation in fasted mice. <i>International Journal of Obesity</i> , <b>1999</b> , 23, 660-5	5.5	15
170	Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. <i>Pancreas</i> , <b>1995</b> , 11, 201-5	2.6	15
169	Glucagon secretory response to hypoglycaemia, adrenaline and carbachol in streptozotocin-diabetic rats. <i>Acta Physiologica Scandinavica</i> , <b>1995</b> , 155, 215-21		15
168	Cholecystikinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: studies on the structure-activity relationship. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1988</b> , 63, 42-5		15
167	GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. <i>Pancreas</i> , <b>1991</b> , 6, 208-15	2.6	15
166	Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129477	3.7	15
165	Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 24-33	6.7	15
164	Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2019</b> , 316, R27-R37	3.2	15
163	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 31-41	3.4	14
162	Long-term effects of alloxan in mice. <i>International Journal of Gastrointestinal Cancer</i> , <b>1995</b> , 17, 197-201		14
161	Influences of gastro-intestinal polypeptides and glucose on glucagon secretion induced by cholinergic stimulation. <i>Hormone and Metabolic Research</i> , <b>1982</b> , 14, 529-32	3.1	14
160	Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice. <i>Physiological Reports</i> , <b>2017</b> , 5, e13280	2.6	13
159	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). <i>BMJ Open Diabetes Research and Care</i> , <b>2018</b> , 6, e000464	4.5	13
158	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse cell function in the GetGoal-M and GetGoal-S trials. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1385-92	3.2	13
157	Effects of six cholecystikinin (CCK) fragments on insulin secretion in the mouse. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1986</b> , 58, 115-20		13



156	Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 988-92	12.7	13
155	Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice. <i>Cell and Tissue Research</i> , <b>2002</b> , 307, 203-9	4.2	13
154	Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. <i>Pancreas</i> , <b>2001</b> , 22, 58-64	2.6	13
153	Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. <i>Diabetologia</i> , <b>1996</b> , 39, 383-90	10.3	13
152	Effects of beta-endorphin, met-enkephalin, and dynorphin A on basal and stimulated insulin secretion in the mouse. <i>International Journal of Gastrointestinal Cancer</i> , <b>1989</b> , 5, 165-78		13
151	Effects of calcitonin, katalcalcin, and calcitonin gene-related peptide on basal and TSH-stimulated thyroid hormone secretion in the mouse. <i>Acta Physiologica Scandinavica</i> , <b>1989</b> , 135, 133-7		13
150	Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 735-41	3.2	12
149	GLP-1 receptor agonists in the treatment of Type 2 diabetes. <i>Diabetes Management</i> , <b>2013</b> , 3, 401-413	0	12
148	Immunoreactive insulin and C-peptide responses to various insulin secretory stimuli in subjects with type 2 diabetes and in control subjects during continuous glucose monitoring. <i>Acta Medica Scandinavica</i> , <b>1981</b> , 210, 337-48		12
147	Protein kinase A inhibition and PACAP-induced insulin secretion in HIT-T15 cells. <i>Annals of the New York Academy of Sciences</i> , <b>1998</b> , 865, 441-4	6.5	12
146	Phospholipase A2 and its potential regulation of islet function. <i>International Journal of Gastrointestinal Cancer</i> , <b>2000</b> , 27, 1-11		12
145	Evidence for contribution by increased cytoplasmic Na <sup>+</sup> to the insulinotropic action of PACAP38 in HIT-T15 cells. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 32602-7	5.4	12
144	Effects of VIP and helodermin on thyroid hormone secretion in the mouse. <i>Neuropeptides</i> , <b>1989</b> , 13, 59-64	3.4	12
143	Inhibition of 2-deoxy-glucose-induced glucagon secretion by muscarinic and alpha-adrenoceptor blockade in the mouse. <i>Diabetes Research and Clinical Practice</i> , <b>1987</b> , 3, 239-42	7.4	12
142	Regulatory peptides in the thyroid gland--a review on their localization and function. <i>Acta Endocrinologica</i> , <b>1991</b> , 124, 225-32		12
141	Capacity to secrete islet hormones after subtotal pancreatectomy for pancreatic cancer. <i>The European Journal of Surgery</i> , <b>1993</b> , 159, 223-7		12
140	Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2018</b> , 314, R639-R646	3.2	11
139	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 242-9	14.6	11

138	Plasma lipid fatty acid composition, desaturase activities and insulin sensitivity in Amerindian women. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2012</b> , 22, 176-81	4.5	11
137	Switching from high-fat to low-fat diet normalizes glucose metabolism and improves glucose-stimulated insulin secretion and insulin sensitivity but not body weight in C57BL/6J mice. <i>Pancreas</i> , <b>2012</b> , 41, 253-7	2.6	11
136	Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. <i>Diabetologia</i> , <b>2002</b> , 45, 1043-4	10.3	11
135	Lowering of circulating insulin and leptin is closely associated following weight reduction after vertical banded gastroplasty in obese women. <i>Diabetes, Obesity and Metabolism</i> , <b>1999</b> , 1, 53-5	6.7	11
134	Effects of glucagon-like peptide-I on glucose turnover in rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1996</b> , 270, E1015-21	6	11
133	Pancreastatin modulates glucose-stimulated insulin secretion from the perfused rat pancreas. <i>Acta Physiologica Scandinavica</i> , <b>1996</b> , 158, 63-70		11
132	Enhancement of insulin secretion during selective blockade of alpha 1- and alpha 2-adrenoceptors in the rat: effects of somatostatin. <i>Acta Physiologica Scandinavica</i> , <b>1982</b> , 115, 257-60		11
131	Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. <i>Anticancer Research</i> , <b>1992</b> , 12, 129-33	2.3	11
130	CHOLECYSTOKININ (CCK 33) CAN STIMULATE PANCREATIC SECRETION BY A LOCAL INTESTINAL MECHANISM IN THE PIG . <i>Biomedical Research</i> , <b>1993</b> , 14, 217-221	1.5	11
129	Regulation of insulin secretion by nerves and neuropeptides. <i>Annals of the Academy of Medicine, Singapore</i> , <b>1999</b> , 28, 99-104	2.8	11
128	Higher Risk of Hypoglycemia with Glimperide Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimperide: Divergent Patient Susceptibilities?. <i>Diabetes Therapy</i> , <b>2014</b> , 5, 459-69	3.6	10
127	Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 1027-33	6.7	10
126	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. <i>European Journal of Pharmacology</i> , <b>2004</b> , 498, 319-23	5.3	10
125	Islet neuronal abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster. <i>Regulatory Peptides</i> , <b>1999</b> , 82, 71-9		10
124	Potential of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric inhibitory polypeptide), bovine GIP, and bovine GIP(1-39). <i>Acta Physiologica Scandinavica</i> , <b>1986</b> , 127, 323-6		10
123	Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse. <i>Hormone and Metabolic Research</i> , <b>1987</b> , 19, 600-3	3.1	10
122	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 2115-2130	3.6	9
121	Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. <i>International Journal of Endocrinology</i> , <b>2015</b> , 2015, 484231	2.7	9

120	Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2011</b> , 300, R1126-33	3.2	9
119	Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 292, E1808-14	6	9
118	A 90-day toxicological evaluation of 1,5-anhydro-d-fructose in Sprague-Dawley rats. <i>Drug and Chemical Toxicology</i> , <b>2005</b> , 28, 263-72	2.3	9
117	Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 397-405	6.5	9
116	Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice. <i>Metabolism: Clinical and Experimental</i> , <b>2002</b> , 51, 12-9	12.7	9
115	Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. <i>Endocrine Research</i> , <b>1995</b> , 21, 583-94	1.9	9
114	Effects of neuropeptide Y on insulin and glucagon secretion in the pig. <i>Neuropeptides</i> , <b>1991</b> , 20, 49-55	3.3	9
113	Effects of pancreatic noradrenaline infusion on basal and stimulated islet hormone secretion in the dog. <i>Acta Physiologica Scandinavica</i> , <b>1988</b> , 132, 143-50		9
112	Effects of alpha- and beta-adrenoceptor stimulation on $45\text{Ca}^{2+}$ efflux and insulin secretion from perfused rat islets. <i>Acta Physiologica Scandinavica</i> , <b>1985</b> , 124, 381-9		9
111	Effect of single-dose DPP-4 inhibitor sitagliptin on $\beta$ cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1080-1085	6.7	9
110	Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?. <i>Diabetologia</i> , <b>2015</b> , 58, 1740-4	10.3	8
109	Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1652-1658	6.7	8
108	Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 99, 25-31	12.7	8
107	Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 1568-76	12.7	8
106	Using albumin to improve the therapeutic properties of diabetes treatments. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 121-9	6.7	8
105	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <i>European Diabetes Nursing</i> , <b>2013</b> , 10, 31-36		8
104	Hyperthyroidism and glucose intolerance. <i>Acta Medica Scandinavica</i> , <b>1986</b> , 220, 5-14		8
103	Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues. <i>Diabetes</i> , <b>2004</b> , 53 Suppl 3, S92-6	0.9	8

102	Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2004</b> , 1, 207-212		8
101	Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice. <i>Regulatory Peptides</i> , <b>2003</b> , 113, 89-94		8
100	Adrenalectomy and chemical sympathectomy by 6-hydroxydopamine. Effects on basal and stimulated insulin secretion. <i>Pflugers Archiv European Journal of Physiology</i> , <b>1981</b> , 390, 17-21	4.6	8
99	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. <i>Acta Endocrinologica</i> , <b>1990</b> , 123, 591-7		8
98	Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. <i>European Journal of Pharmacology</i> , <b>2016</b> , 780, 46-52	5.3	8
97	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1283-1285	3.2	7
96	Incretin hormone receptors are required for normal beta cell development and function in female mice. <i>Peptides</i> , <b>2016</b> , 79, 58-65	3.8	7
95	Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. <i>Diabetologia</i> , <b>2014</b> , 57, 801-8	10.3	7
94	Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2017</b> , 33, e2879	7.5	7
93	Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 715-70.9		7
92	No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. <i>European Journal of Endocrinology</i> , <b>1997</b> , 137, 643-9	6.5	7
91	Insulin secretion by gastrin-releasing peptide in mice: ganglionic versus direct islet effect. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 274, E124-9	6	7
90	Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 590-598	6.7	7
89	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5). <i>Obesity Science and Practice</i> , <b>2019</b> , 5, 130-140	2.6	6
88	Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique in Female Mice. <i>Endocrinology</i> , <b>2015</b> , 156, 3866-71	4.8	6
87	Altered glucose tolerance in women with deliberate self-harm. <i>Psychoneuroendocrinology</i> , <b>2009</b> , 34, 878-83		6
86	DPP-4 inhibitors. <i>Insulin</i> , <b>2009</b> , 4, 15-31		6
85	Disturbed alpha-cell function in mice with beta-cell specific overexpression of human islet amyloid polypeptide. <i>Experimental Diabetes Research</i> , <b>2008</b> , 2008, 304513		6

84	The effects of PACAP on insulin secretion and glucose disposal are altered by adrenalectomy in mice. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 921, 251-8	6.5	6
83	Inhibitory effect of D-myo-inositol-1,2,6-trisphosphate on glucose-stimulated insulin secretion in the mouse. <i>Neuropeptides</i> , <b>1992</b> , 21, 163-6	3.3	6
82	Insulin secretion induced by glucose and by stimulation of beta 2 -adrenoceptors in the rat. Different sensitivity to somatostatin. <i>Acta Physiologica Scandinavica</i> , <b>1981</b> , 112, 421-6		6
81	Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. <i>Anticancer Research</i> , <b>1992</b> , 12, 881-4	2.3	6
80	Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 675-685	3.9	6
79	The dynamic incretin adaptation and type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 620-2	5.6	5
78	Intraoperative secretion of intact parathyroid hormone and amino-terminal parathyroid hormone fragments from normal parathyroid glands associated with solitary parathyroid adenoma. <i>World Journal of Surgery</i> , <b>1997</b> , 21, 30-4; discussion 34-5	3.3	5
77	Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. <i>Journal of Molecular Endocrinology</i> , <b>2008</b> , 40, 93-100	4.5	5
76	Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2008</b> , 5, 79-90		5
75	ANF inhibits glucose-stimulated insulin secretion in mouse and rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1988</b> , 255, E579-82	6	5
74	A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2006</b> , 291, R131-7	3.2	5
73	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance <b>1996</b> , 39, 1099		5
72	Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2019</b> , 2, e00056	2.7	4
71	Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice. <i>Peptides</i> , <b>2015</b> , 71, 66-71	3.8	4
70	The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvz036	0.4	4
69	Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. <i>Diabetes and Metabolism</i> , <b>2015</b> , 41, 6S3-6S8	5.4	4
68	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. <i>Current Enzyme Inhibition</i> , <b>2012</b> , 7, 205-217	0.5	4
67	Study on administration of 1,5-anhydro-D-fructose in C57BL/6J mice challenged with high-fat diet. <i>BMC Endocrine Disorders</i> , <b>2010</b> , 10, 17	3.3	4

66	Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats. <i>Journal of Endocrinology</i> , <b>1997</b> , 152, 495-501	4.7	4
65	The negative association between serum free testosterone and leptin is dependent on insulin-like growth factor-binding protein 1 in healthy young and middle-aged men. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 493-8	3.4	4
64	Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. <i>Endocrine</i> , <b>1995</b> , 3, 367-9		4
63	Glucagon-like peptide-1(7-36)amide and cytoplasmic calcium in insulin producing cells. <i>Acta Physiologica Scandinavica</i> , <b>1996</b> , 157, 333-41		4
62	Cysteamine and the endocrine pancreas: immunocytochemical, immunochemical, and functional aspects. <i>Cell and Tissue Research</i> , <b>1989</b> , 256, 159-66	4.2	4
61	Effects of helospectin I on insulin and glucagon secretion in the mouse. <i>British Journal of Pharmacology</i> , <b>1991</b> , 102, 916-8	8.6	4
60	Kinetics of radioiodine released from prelabelled thyroid gland in vivo: influence of propylthiouracil. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1987</b> , 61, 69-71		4
59	The effects of epinephrine on islet hormone secretion in the dog. <i>International Journal of Gastrointestinal Cancer</i> , <b>1988</b> , 3, 375-88		4
58	Failure of somatostatin to eliminate the glucagon release induced by baroreceptor unloading in the cat. <i>Acta Physiologica Scandinavica</i> , <b>1978</b> , 103, 478-80		4
57	GABA inhibits thyroid hormone secretion in the mouse. <i>Thyroidology</i> , <b>1989</b> , 1, 105-8		4
56	Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 611147	5.7	4
55	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. <i>Diabetes Therapy</i> , <b>2016</b> , 7, 583-90	3.6	4
54	The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. <i>European Endocrinology</i> , <b>2017</b> , 13, 56-61	3.4	3
53	Disassociated relation between plasma tumor necrosis factor-alpha, interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance. <i>Diabetology and Metabolic Syndrome</i> , <b>2010</b> , 2, 38	5.6	3
52	Galanin exerts dual action on inositol-specific phospholipase C activity in isolated pancreatic islets. <i>Endocrine Journal</i> , <b>1997</b> , 44, 283-8	2.9	3
51	The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2006</b> , 16 Suppl 1, S17-21	4.5	3
50	Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas. <i>International Journal of Gastrointestinal Cancer</i> , <b>1996</b> , 20, 103-7		3
49	Pancreastatin inhibits insulin secretion and exocrine pancreatic secretion in the pig. <i>Diabetes Research</i> , <b>1990</b> , 14, 93-6		3

48	Plasmapheresis and haemodialysis in a case of septic cholangitis complicated by hepatic and renal failure. Case report. <i>Acta Chirurgica Scandinavica</i> , <b>1988</b> , 154, 157-9		3
47	Exenatide: a novel treatment of Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 207-222		3
46	The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice. <i>Peptides</i> , <b>2021</b> , 135, 170434	3.8	3
45	Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. <i>Diabetologia</i> , <b>1995</b> , 38, 395-402	10.3	3
44	Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1911-1920	6.7	2
43	Evidence for time dependent variation of glucagon secretion in mice. <i>Peptides</i> , <b>2016</b> , 76, 102-7	3.8	2
42	Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes. <i>Diabetes Management</i> , <b>2012</b> , 2, 453-464		2
41	MODULATION OF FASTED AND POSTPRANDIAL PLASMA LIPIDS IN HEALTHY VOLUNTEERS BY A DIETARY MIXTURE OF OMEGA-3 FATTY ACIDS AND CONJUGATED LINOLEIC ACID. <i>Journal of Food Lipids</i> , <b>2009</b> , 16, 499-513		2
40	Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin Following Ingestion of Different Classes of Macronutrients.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	2
39	Recurrent laryngeal nerve palsy after thyroid and parathyroid surgery. Experience from Lund University. <i>Thyroidology</i> , <b>1992</b> , 4, 87-9		2
38	Insulin secretion in neonatally streptozotocin-injected mice. <i>Diabetes Research</i> , <b>1989</b> , 11, 185-9		2
37	Interferon-alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion. <i>The European Journal of Surgery</i> , <b>1993</b> , 159, 209-12		2
36	Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse. <i>Diabetologia</i> , <b>1981</b> , 21, 54-59	10.3	2
35	Glucose-lowering action through targeting islet dysfunction in type2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1128-1135	3.9	2
34	The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 665537	5.7	2
33	Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 680153	5.7	2
32	Islet adaptation in GIP receptor knockout mice. <i>Peptides</i> , <b>2020</b> , 125, 170152	3.8	2
31	Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease. <i>Acta Medica Scandinavica</i> , <b>1984</b> , 215, 487-91		1

30	Function of reduced-size liver transplant in the rat. <i>Research in Experimental Medicine</i> , <b>1997</b> , 197, 91-9		1
29	Pituitary adenylate cyclase activating polypeptide stimulates insulin secretion in a glucose-dependent manner in vivo. <i>Annals of the New York Academy of Sciences</i> , <b>1998</b> , 865, 466-70	6.5	1
28	Incretins and islet function. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2006</b> , 13, 154-161		1
27	PACAP27 sensitizes glucose induced insulin secretion in INS-1 cells. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 921, 456-9	6.5	1
26	Signals adapting the beta cells to changes in insulin sensitivity. <i>International Congress Series</i> , <b>2003</b> , 1253, 105-113		1
25	Relation between malnutrition and development of diabetes mellitus. <i>International Journal of Gastrointestinal Cancer</i> , <b>1999</b> , 26, 125-30		1
24	Effects of minor increase in serum calcium on the immunoheterogeneity of parathyroid hormone in healthy subjects and in patients with primary hyperparathyroidism. <i>Hormone Research</i> , <b>1995</b> , 43, 294-9		1
23	Plasma neuropeptide Y in impaired glucose tolerance. <i>Acta Diabetologica</i> , <b>1996</b> , 33, 295-7	3.9	1
22	Subtotal pancreatectomy with stapling the pancreatic remnant. <i>Langenbecks Archiv Fur Chirurgie</i> , <b>1990</b> , 375, 359-61		1
21	Inhibition by galanin and by high K <sup>+</sup> of human basophil histamine release triggered by calcium ionophores but not responses induced by anti-IgE, chemotactic peptide or phorbol ester. <i>British Journal of Pharmacology</i> , <b>1991</b> , 103, 1381-4	8.6	1
20	Effects of glucagon and pentagastrin on glibenclamide-induced insulin release. <i>Acta Physiologica Scandinavica</i> , <b>1980</b> , 109, 261-4		1
19	Reduction of secretion from a small-bowel fistula by somatostatin. Case report. <i>Acta Chirurgica Scandinavica</i> , <b>1989</b> , 155, 205-8		1
18	Omega-3 fatty acids and other polyunsaturated fatty acids and weight control <b>2007</b> , 281-304		1
17	Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats <b>1996</b> , 39, 649		1
16	Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
15	PACAP and the Endocrine Pancreas. <i>Growth Hormone</i> , <b>2003</b> , 185-206		0
14	Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice. <i>Peptides</i> , <b>2021</b> , 146, 170650	3.8	0
13	Alain Ktorza, PhD. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19 Suppl 1, 3	6.7	



- 12 Neuropeptides and islet hormone secretion **2015**, 125-135
- 11 Extrapaneatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition. *Cardiovascular Endocrinology*, **2016**, 5, 82-85
- 10 Reply to the letter by P. Guillausseau Regarding Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet Closed *Current Diabetes Reports*, **2011**, 11, 463-463 5.6
- 9 Potential clinical use of the EDTA-infusion test. *Clinical Chemistry and Laboratory Medicine*, **1993**, 31, 353-8 5.9
- 8 Calcium stimulates the release of calcitonin gene-related peptide from the canine thyroid. *American Journal of Physiology - Endocrinology and Metabolism*, **1989**, 256, E597-9 6
- 7 Galanin inhibits tolbutamide-stimulated insulin secretion in the perfused pig pancreas. *Diabetes Research*, **1992**, 19, 59-62
- 6 Effects of gastrin-releasing peptide on basal and stimulated thyroid hormone secretion in the mouse. *Acta Endocrinologica*, **1989**, 120, 245-9
- 5 Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men. *Endocrinology, Diabetes and Metabolism*, **2020**, 3, e00141 2.7
- 4 Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. *International Journal of Endocrinology*, **2016**, 2016, 3452898 2.7
- 3 Enhanced insulin sensitivity mediated by adipose tissue browning perturbs islet morphology and hormone secretion in response to autonomic nervous activation in female mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2016**, 310, E81-90 6
- 2 Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. *Diabetologia*, **1994**, 37, 871-878 10.3
- 1 Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. *Diabetologia*, **1996**, 39, 383-390 10.3